A. Before offering a batch of medical
marijuana or of a marijuana product for sale or dispensing to a qualifying
patient or designated caregiver, a dispensary shall ensure that:
1. Except as provided in subsection (A)(2) or
(3), each batch of medical marijuana or marijuana product is tested in
compliance with requirements in
R9-17-404.03,
R9-17-404.04, and Table
3.1;
2. Each batch of a marijuana
product is tested according to requirements in
R9-17-404.03,
R9-17-404.04, and Table 3.1 for, as
applicable:
a. At least potency and microbial
contaminants other than mycotoxins if the marijuana product was prepared from
another marijuana product, such as a concentrate or tincture, that is in
compliance with requirements in
R9-17-404.03,
R9-17-404.04, and Table 3.1, using
none of the following:
i. A temperature above
which any analyte could chemically decompose or react with a component of the
marijuana product;
ii. A pressure
above which any analyte could chemically decompose or react with a component of
the marijuana product;
iii. A
process by which any analyte in the marijuana product that is in compliance
with requirements in
R9-17-404.03,
R9-17-404.04, and Table 3.1 may be
further concentrated; or
iv. A
solvent other than water; or
b. All analytes except:
i. Ethanol if the marijuana product is
intended to contain ethanol; or
ii.
For a marijuana product intended for topical application, isopropanol if the
marijuana product is intended to contain isopropanol; and
3. If the results of testing of
the dispensary's medical marijuana and marijuana products for heavy metals,
according to
R9-17-404.03, indicate that the
medical marijuana and marijuana products are in compliance with Table 3.1 for a
period of at least six consecutive months:
a.
Each batch of medical marijuana or a marijuana product is tested according to
requirements in
R9-17-404.03,
R9-17-404.04, and Table 3.1 for all
analytes except heavy metals; and
b. At least once every three months, each
batch of medical marijuana or a marijuana product is tested according to
requirements in
R9-17-404.03 and Table 3.1 for
heavy metals.
B. A dispensary shall ensure that:
1. Until laboratory testing has been
completed and testing results received by the dispensary that comply with
requirements in
R9-17-404.03,
R9-17-404.04, and Table 3.1, a
batch of marijuana or of a marijuana product is stored in a location away from
medical marijuana and marijuana products offered for dispensing;
2. Except as provided in subsection (D), only
one sample of each batch of medical marijuana or marijuana product is collected
according to ANSI/ASQ Standard Z1.4 (2018), General Inspection Level II,
incorporated by reference, including no future editions, and available at
https://asq.org/quality-resources/z14-z19,
including:
a. Use, as applicable, of one of
the following sampling methods:
i. Top,
middle, and bottom sampling using a sample thief, a device consisting of two
nested tubes with one or more aligned slots through which a sample may be
collected and then sealed into the inner tube by rotating the outer
tube;
ii. Star pattern sampling
from the top, middle, and bottom of each storage container;
iii. Collecting discrete incremental units of
a batch, such as every tenth unit or every twentieth drop; or
iv. Quartering until the sample reaches the
size specified in subsection (B)(3); and
b. For sampling methods specified in
subsections (B)(2)(a)(i) through (iii), quartering the volume of the aggregated
portions collected to obtain the sample size specified in subsection
(B)(3);
3. The size of
the sample provided to a laboratory is sufficient for testing and, if
necessary, retesting;
4. Each
sample in subsection (B)(3) is packaged in a container made of:
a. The same material that would be used for
dispensing, or
b. Another material
that will not react with or leach into the sample;
5. Each packaged sample is labeled with the:
a. The dispensary's registry identification
number;
b. The amount, strain, and
batch number of the medical marijuana or marijuana product;
c. The analytes for which testing is being
requested;
c.d. The storage
temperature for the marijuana or marijuana product; and
d.e. The
date of sampling;
6. A
packaged sample in subsection (B)(4) is submitted to a laboratory that:
a. Has a laboratory registration certificate
issued by the Department, and
b. Is
approved for testing by the Department for an analyte for which testing is
being requested;
7.
Except as specified in subsections (A)(2) and (3) and (C)(1), as applicable,
the samples in subsection (B)(4) are tested for each analyte specified in Table
3.1 by a laboratory that is approved by the Department for testing the
analyte;
8. Only batches of
marijuana or marijuana products for which laboratory testing results in
subsection (B)(7) are in compliance with the requirements in
R9-17-404.03,
R9-17-404.04, and Table 3.1 are
offered for sale or dispensing; and
9. Except as provided in subsection (C), any
batch of marijuana or marijuana product that does not comply with the
requirements in
R9-17-404.03,
R9-17-404.04, and Table 3.1 is
remediated, if applicable, or destroyed according to policies and
procedures.
C. If a
dispensary receives a final report of testing, specified in
R9-17-404.06(B)(3),
from a laboratory that indicates that a batch of medical marijuana or marijuana
product does not comply with the requirements in
R9-17-404.03,
R9-17-404.04, and Table 3.1, the
dispensary:
1. Within seven days after
receiving the final report of testing, may request retesting of the remaining
portion of the sample in subsection (B)(4) for all analytes that do not comply
with the requirements in
R9-17-404.03,
R9-17-404.04, and Table 3.1 by no
more than two other laboratories that are independent of a laboratory
conducting a test included in the final report of testing and that are approved
by the Department for testing the analytes;
2. If the final report of testing conducted
according to subsection (C)(1) from another, independent laboratory indicates
that any analyte tested for according to subsection (C)(1) does not comply with
the requirements in
R9-17-404.03,
R9-17-404.04, and Table 3.1, shall
remediate, if applicable, or destroy the batch of medical marijuana or
marijuana product according to policies and procedures; and
3. If the final report of testing from each
of the two other independent laboratories, allowed according to subsection
(C)(1), indicates that all analytes tested for according to subsection (C)(1)
comply with the requirements in
R9-17-404.03,
R9-17-404.04, and Table 3.1
a. Shall ensure that the batch of
medical marijuana or marijuana product is not offered for sale or dispensing;
and
b. May request retesting of the
remaining portion of the sample in subsection (B)(4) for the analytes that do
not comply with the requirements in R9-17-404.03, R9-17-404.04, and Table 3.1
by a third, independent laboratory that is approved by the Department for
testing the analytes; and
4. If the dispensary requested
retesting of the remaining portion of the sample in subsection (B)(4) for an
analyte by a third, independent laboratory according to subsection
(C)(3)(b):
a. If the final report of testing
from the third, independent laboratory indicates that the analyte tested for
according to subsection (C)(3) complies with the requirements in R9-17-404.03,
R9-17-404.04, and Table 3.1, may offer the batch of medical marijuana
or marijuana product for sale or dispensing
b. If the final report of testing
from the third, independent laboratory indicates that an analyte tested for
according to subsection (C)(3) does not comply with the requirements in
R9-17-404.03, R9-17-404.04, and Table 3.1, shall remediate, if applicable, or
destroy the batch of medical marijuana or marijuana product according to
policies and procedures.
D. A dispensary may request retesting of a
batch of medical marijuana or marijuana product using a second sample if:
1. The batch of marijuana or marijuana
product is still in the possession of the dispensary;
2. The dispensary receives notification from
the Department, a marijuana establishment, or another dispensary that indicates
that the final report of testing from a laboratory, specified in
R9-17-404.06(B)(3),
for the batch of medical marijuana or marijuana product may be
inaccurate;
3. The dispensary:
a. If the notification in subsection (D)(2)
is from a marijuana establishment or another dispensary, informs the Department
that the final report of testing may be inaccurate, providing the name of the
notifying dispensary or marijuana establishment;
b. Collects the second sample according to
subsections (B)(2) and (3);
b.c. Packages and labels
the sample according to subsections (B)(4) and (5); and
c.d.
Submits the sample to a second, independent laboratory that is approved by the
Department for testing the analytes; and
4. The dispensary follows the requirements in
subsections (C)(1) through (3) in determining whether the batch of medical
marijuana or marijuana product:
a. May be
offered for sale or dispensing, or
b. Is required to be remediated, if
applicable, or destroyed.
E. A dispensary shall ensure that remediation
of a batch of marijuana or of a marijuana product that has undergone laboratory
testing and does not comply with the requirements in
R9-17-404.03,
R9-17-404.04, and Table 3.1:
1. Is performed according to policies and
procedures,
2. Uses a method that
is appropriate to address an analyte not in compliance with Table 3.1,
and
3. Does not introduce or
produce a substance in a concentration that is known to be harmful to
humans.
F. If a batch of
medical marijuana or a marijuana product is remediated, a dispensary shall
submit samples from the remediated batch for laboratory testing according to
subsection (B).
G. A dispensary
shall provide to the Department upon request a sample of the dispensary's
inventory of medical marijuana or a marijuana product of sufficient quantity to
enable the Department to conduct an analysis of the medical marijuana or
marijuana product.
Notes
Ariz. Admin.
Code §
R9-17-317.01
Adopted by
final exempt rulemaking at
26
A.A.R. 734, effective 4/2/2020. Amended by exempt rulemaking at
26
A.A.R. 2991, effective 11/1/2020. Amended by final exempt rulemaking at
27
A.A.R. 111, effective 1/15/2021. Amended by final expedited rulemaking at
28
A.A.R. 2562, effective 9/8/2022. Amended by final rulemaking at
29
A.A.R. 2396, effective 10/1/2023.